Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Primary Breast Cancer ER+ve × enzalutamide × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 18 Triple Negative Breast Neoplasms 5 Prostatic Neoplasms 4 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Melanoma 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thrombocytosis 1 Stomach Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Primary Myelofibrosis 1 Primary Breast Cancer ER+ve 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neoplasms, Squamous Cell 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mesothelioma 1 Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Liposarcoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1

Interventions

exemestane 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02676986 2024-07-05

ARB

Queen Mary University of London

Phase 2 Completed

Primary Breast Cancer ER+ve

Data powered by HemOnc (CC BY 4.0) Colophon ⚡